Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 202

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 202
---
                                                  |
| Co-opted                  | None                                  | None                                           | Jean-Paul Kress(a)                                    |
| Other                     | None                                  | None                                           | Gilles Schnepp(b)                                     |

(a) Jean-Paul Kress was co-opted as a director by the Board of Directors meeting of December 19, 2024 with effect from January 1, 2025, to replace Gilles Schnepp, who resigned from office effective December 31, 2024. (b) Gilles Schnepp resigned from office as a director effective December 31, 2024. Changes in Board membership to be submitted for shareholder approval at the Annual General Meeting on April 30, 2025

| Expiry of term of office  | Fabienne Lecorvaisier |
| Proposed reappointments   | See below             |
| Proposed new appointments | See below             |
| Ratification of co-option | Jean-Paul Kress       |
| Other                     | None                  |

| SANOFIFORM 20-F2024 | 97 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

The terms of office of Carole Ferrand, Barbara Lavernos, Fabienne Lecorvaisier, Emile Voest and Antoine Yver will expire at the close of the Annual General Meeting to be held on April 30, 2025. The Appointments, Governance and CSR Committee held on February 4, 2025 recommended the renewal of the mandates of Carole Ferrand, Barbara Lavernos, Emile Voest and Antoine Yver. Proposed resolutions to be submitted for shareholder approval at the Annual General Meeting on April 30, 2025 will be approved by the Board of Directors on March 2025 and will be communicated in the notice of meeting of said Annual General Meeting. To date, however, it is specified that: • Fabienne Lecorvaisier's term of office cannot be renewed because she will have served as a director of Sanofi for 12 years and will therefore no longer be considered independent according to the AFEP-MEDEF Code; and • the ratification of the co-option of Jean-Paul Kress will be proposed. In addition, t he terms of office of Wolfgang Laux and Yann Tran as directors representing employees will expire at the close of the Annual General Meeting of April 30, 2025. Designation of directors representing employees will be made in accordance with Article 11 of our